DDIT3 and diffuse large B-cell lymphoma: However, up to 40% of all patients develop relapsed/refractory disease (R/R) where ABC-DLBCL generally shows a poorer prognosis and a higher incidence of R-CHOP resistance [1,7,8,9,10].